Greg has a Ph.D. in molecular biology from University of California, Berkeley, where he helped invent a promising new way to treat cancer with immunotherapy. He has 20 years of experience in biomedical research, including phenotypic screening, cell biology, and immunology. Greg has led Remedy Plan from inception through development of its drug screening platform to the optimization of novel first-in-class cancer therapeutics.

Dennise provides project leadership for our scientific operations and is responsible for development and implementation of effective research practices. She has worked in biomedical research for over 10 years, most recently at the National Institutes of Health. She holds a B.S. from the University of Puerto Rico at Cayey and a Ph.D. from Tufts University School of Medicine.

Allison is an environmental scientist with a Masters of Science in oceanography and a Masters of Public Policy from the Harvard Kennedy School. She has expertise in developing and implementing strategic direction, leading large scale collaborative research publications, and managing scientific assessments across private, government, and academic institutions. She has a knack for making complex concepts accessible to a broad range of audiences.

Yushma brings extensive pharmaceutical drug discovery experience to the Remedy Plan team. She has worked for 10 years in the pharmaceutical industry for companies such as GlaxoSmithKline, Galderma-NSH, and Johnson & Johnson, where she successfully developed new clinical drug candidates. After graduating from the ESPCI in Paris, Yushma obtained her Ph.D. in Chemistry from Imperial College London.

Min earned her M.S. in chemistry from University of Maryland at Baltimore County and her Ph.D. in molecular biology and genetics from Johns Hopkins University School of Medicine. She conducted postdoctoral research at Memorial Sloan Kettering Cancer Center on the crucial mechanisms of DNA replication and repair, and later at Johns Hopkins University School of Medicine on translational studies of acute myeloid leukemia with a focus on identifying novel therapeutic targets.

Tim has a Ph.D. in biology from Carnegie Mellon University and performed his postdoctoral work at the University of Maryland School of Medicine in Baltimore. His research background is in the underlying cellular and molecular biology of proteins that maintain proper cell health. He has applied this to the study of diverse research topics such as diabetes and neurodegenerative diseases.

Caroline joins the Remedy Plan team with a strong background in oncology drug discovery. She received her Ph.D. in Cancer Research from the University of Nebraska Medical Center and conducted her postdoctoral research as a fellow at Memorial Sloan Kettering Cancer Center in NYC. Throughout her training, Caroline has focused on characterization of mechanisms of action and target identification studies to identify new cancer therapies.

Adam holds a M.S. in biological sciences from Indiana University of Pennsylvania and a B.S. from Longwood University, where he gained experience in tumor immunology & pharmacology. At Remedy Plan, Adam conducted a high-throughput screen and continues to run validation assays to identify novel therapeutic compounds. He also provides support to Remedy Plan's lead optimization efforts as part of characterizing novel therapeutic compounds.

Mohamad graduated from George Mason University with a B.S. in biology and concentrations in molecular biology and biotechnology. His research includes work to optimize a nanotechnology called the nanotrap, to trap antigens from diseases like Lyme disease, HIV, and tuberculosis. At Remedy Plan, Mohamad is helping accelerate the process of drug candidate selection by testing analog compounds on different cancerous cell lines.

Mona holds an M.B.A from Park University and a Bachelor of Pharmacy from Gujarat Technological University. She joins the Remedy Plan team to provide administrative support with expertise in project coordination. Prior to joining Remedy Plan, she worked in pharmaceutical API research and development, where she gained experience in quality assurance and good laboratory practices.

Frank is a Professor at the University of California San Francisco (UCSF) Comprehensive Cancer Center and founder of Onyx Pharmaceuticals, where he initiated drug discovery efforts that led to the approval of multiple cancer treatments (renal cell, liver, and nasopharyngeal). Frank is a Fellow of the Royal Society (FRS) and member of the National Academies of Science.

Daniel is a Distinguished Chair in Global Public Health and Infectious Diseases and Professor of Biochemistry, Biophysics and Structural Biology at the University of California Berkeley. He is a member of the National Academies of Science, an NIH Merit Award recipient, and serves on the advisory board of Aduro Biotech, a clinical-stage cancer immunotherapy company.

Vahe is retired from a career in cancer pharmaceutical R&D, biotherapeutics, and immuno-oncology. He is currently serving as a consultant and advisor to biotechs and non-profits.

Ron is a professor in Baylor's Department of Neuroscience at the Stem Cells and Regenerative Medicine Center, where his research focuses on neural development, stem cells, and cancer biology. He received his Ph.D. from U.C. Berkeley and did his post-doctoral fellowship at U.C. San Francisco.

Sol is founder and CEO of Quality Biological, Inc., a primary manufacturer of supplies for cell culture and molecular biology applications. He has served on the Board of Directors for Montgomery General Hospital, Macklin Business Institute, and the Strathmore Hall Foundation, among others, and has chaired the Economic Advisory Council of Montgomery County.

Vic has been a Venture Partner and Advisor to Bay City Capital since 2007. He was formerly President of Venture Management at Baxter Healthcare Corporation where he  was responsible for the creation and management of Baxter Healthcare’s interests in development-stage biotech companies. He has served on the board of directors of more than a dozen development-stage biotech companies.